Multiple Myeloma: all 3,712 studies
Page 27 of 38. Open to participants first (752), then studies with results posted, then the rest; newest registration first within each.
- Comparing Intermediate-dose CTX+ G-CSF Plus or Not rhTPO for PB CD34+ Cells Mobilization in MM PatientsStatus unknownNCT02572596Not applicable
- Study of Carfilzomib in Multiple Myeloma Relapsed After High-dose Melphalan With Autologous Stem Cell SupportStatus unknownNCT02572492Phase 2
- HDAC Inhibitor AR-42 and Pomalidomide in Treating Patients With Relapsed Multiple MyelomaCompletedNCT02569320Phase 1
- An Expanded Treatment Protocol of Panobinostat in Combination Therapy for Relapsed, and Relapsed and Refractory Multiple MyelomaNo longer availableNCT02568943
- Observational Study in Participants With Chronic Lymphocytic Leukemia (CLL), Multiple Myeloma (MM) and Non-Hodgkin's Lymphoma (NHL) in Latin AmericaCompletedNCT02559583
- Modified Bortezomib-based Combination Therapy for Multiple MyelomaStatus unknownNCT02559154Phase 4
- A Study to Collect and Evaluate the Safety and Efficacy Information of Korean Multiple Myeloma Patients Treated With REVLIMID®, After Approval of Marketing Authorization for New Drug in KoreaCompletedNCT02556905
- Treatment of Relapsed/Refractory Multiple Myeloma (rrMM) With Pomalidomide in Clinical PracticeCompletedNCT02555839
- CART-BCMA Cells for Multiple MyelomaCompletedNCT02546167Phase 1
- Ixazomib with Pomalidomide, Clarithromycin and Dexamethasone in Treating Patients with Multiple MyelomaActive, not recruitingNCT02542657Phase 1/2
- Expanded Access Single Named Patient Program With Elotuzumab (BMS-901608) for the Treatment of Patient R-A With Relapsed/Refractory Multiple MyelomaNo longer availableNCT02541643
- Lenalidomide Maintenance in Plasma Cell MyelomaActive, not recruitingNCT02538198Phase 2
- Non-interventional Study of Lenalidomide / Dexamethasone as First Line Therapy in Patients With Multiple MyelomaCompletedNCT02537808
- An Observational Study to Assess Safety and Outcome of the Various Medication Usage Patterns in Clinical Routine Practice in Patients Receiving Lenalidomide.CompletedNCT02528838
- A Study of Daratumumab With the Addition of Recombinant Human Hyaluronidase (rHuPH20) for the Treatment of Participants With Relapsed or Refractory Multiple MyelomaCompletedNCT02519452Phase 1
- Haploidentical Bone Marrow Stem Cell Transplantation in Patients With Multiple MyelomaStatus unknownNCT02519114Phase 1/2
- A Study to Evaluate the Safety, Pharmacokinetics, and Efficacy of Isatuximab in Patients With Multiple MyelomaCompletedNCT02514668Phase 1
- Wild-Type Reovirus, Bortezomib, and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple MyelomaCompletedNCT02514382Phase 1
- Study of Isatuximab Combined With Bortezomib + Cyclophosphamide + Dexamethasone (VCD) and Bortezomib + Lenalidomide + Dexamethasone (VRD) in Newly Diagnosed Multiple Myeloma (MM) Non Eligible for Transplant or No Intent for Immediate TransplantationCompletedNCT02513186Phase 1
- Thiotepa-based Conditioning for Allogeneic Stem-cell Transplantation (SCT) in Lymphoid MalignanciesStatus unknownNCT02507479Phase 2
- Combination Chemotherapy and Donor Stem Cell Transplant Followed by Ixazomib Citrate Maintenance Therapy in Treating Patients With Relapsed High-Risk Multiple MyelomaCompletedNCT02504359Phase 1
- A Study of JNJ-54767414 (Daratumumab) in Combination With Bortezomib and Dexamethasone (D-Vd) in Japanese Participants With Relapsed or Refractory Multiple MyelomaCompletedNCT02497378Phase 1
- A Phase III Trial on the Effect of Elotuzumab in VRD Induction /Consolidation and Lenalidomide Maintenance in Patients With Newly Diagnosed MyelomaCompletedNCT02495922Phase 3
- Lonquek for Autologous Stem Cell MobilizationStatus unknownNCT02488382Phase 1/2
- Early Access Treatment With Daratumumab for (Relapsed or Refractory) Multiple MyelomaApproved for marketingNCT02477891
- Study of Gene Modified Donor T Cell Infusion in Patients With Recurrent Disease After Allogeneic TransplantActive, not recruitingNCT02477878Phase 1
- Observational Study to Evaluate the Efficacy and Safety of Bortezomib, Melphalan, Prednisone (VMP) in Participants With Multiple MyelomaCompletedNCT02474563
- Lenalidomide & Adriamycin & Dexamethasone (RAD) in Newly Diagnosed, Multiple Myeloma PatientsCompletedNCT02471820Phase 2
- NMP in Relapsed / Refractory MyelomaCompletedNCT02468687Phase 1
- The Effects of Huang-Lian-Jie-Du-Tang（HLJDT) on the Survival of Patients With Multiple Myeloma in Maintain TherapyStatus unknownNCT02467647Phase 1
- Relapse Myeloma; Cyclofosfamide; Bortezomib; MaintenanceCompletedNCT02467010Phase 2
- Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)Active, not recruitingNCT02465060Phase 2
- Dose-Escalation Study of ABBV-838, an Antibody Drug Conjugate, in Subjects With Relapsed and Refractory Multiple MyelomaTerminatedNCT02462525Phase 1
- Phase II Randomised Trial of Cyclophosphamide & Dexamethasone in Combination With Ixazomib in Relapsed or Refractory Multiple Myeloma.CompletedNCT02461888Phase 2
- T Cell Receptor-transduced T Cells Targeting NY-ESO-1 for Treatment of Patients With NY-ESO-1- Expressing MalignanciesStatus unknownNCT02457650Phase 1
- Impact of DMSO Concentrations on Hematopoietic Recovery After Autologous HSC Transplantation.CompletedNCT02452099Not applicable
- Fungemia in Hematologic MalignanciesCompletedNCT02451592
- Allogeneic Stem Cell Transplantation for Patients With Multiple MyelomaWithdrawnNCT02447055Early Phase 1
- Non-interventional Study on Salvage Auto in Relapsed MyelomaCompletedNCT02439476
- Exercise in Patients With Multiple MyelomaCompletedNCT02439112Not applicable
- iCare for Cancer PatientsTerminatedNCT02435550Not applicable
- Symbenda Post-Marketing Surveillance (PMS)CompletedNCT02434484
- A Study of Atezolizumab (Anti-Programmed Death-Ligand 1 [PD-L1] Antibody) Alone or in Combination With an Immunomodulatory Drug and/or Daratumumab in Participants With Multiple Myeloma (MM)CompletedNCT02431208Phase 1
- Clinical Study of CWP232291 in Relapsed or Refractory Myeloma PatientsCompletedNCT02426723Phase 1
- Elotuzumab and Lenalidomide After Stem Cell Transplant in Treating Patients With Newly Diagnosed Multiple MyelomaActive, not recruitingNCT02420860Phase 2
- "Monoclonal Antibodies for Treatment of Multiple Myeloma. Emphasis on the CD38 Antibody Daratumumab "CompletedNCT02419118Phase 2/3
- Carfilzomib in Treatment Patients Under 65 Years With High Risk Smoldering Multiple MyelomaActive, not recruitingNCT02415413Phase 2
- Ixazomib in Combination With Thalidomide - Dexamethasone in Patients With Relapsed and/or Refractory Multiple MyelomaCompletedNCT02410694Phase 2
- Phase I Trial of VS-6766 Alone and in Combination With EverolimusCompletedNCT02407509Phase 1
- Pomalidomide in Relapsed and Refractory Multiple Myeloma (RRMM)Active, not recruitingNCT02406222Phase 2
- Trial Studying Maintenance Treatment With Lenalidomide and Dexamethasone Versus Lenalidomide, Dexamethasone and MLN9708 After Autologous Hematopoietic Stem Cell Transplantation in Patients With Newly-diagnosed Symptomatic Multiple MyelomaCompletedNCT02406144Phase 3
- Front-line Therapy With Carfilzomib, Lenalidomide, and Dexamethasone InductionCompletedNCT02405364Phase 2
- Imageguided Theranostics in Multiple MyelomaCompletedNCT02403102
- A Open-label Study of Ultra-High Dose Dexamethasone for Relapsed Multiple MyelomaWithdrawnNCT02402725Phase 2
- ATRA, Celecoxib, and Itraconazole as MaintenanceCompletedNCT02401295Phase 1
- Study of ACY-241 Alone and in Combination With Pomalidomide and Dexamethasone in Multiple MyelomaTerminatedNCT02400242Phase 1
- Post-authorisation Study of Biological Relapse in Patients With Multiple MyelomaTerminatedNCT02394210
- A Study Evaluating the Safety and Pharmacokinetics of ABBV-075 in Subjects With CancerCompletedNCT02391480Phase 1
- Study of Selinexor (KPT- 330), Lenalidomide, & Dexamethasone in Relapsed/Refractory Multiple Myeloma PatientsWithdrawnNCT02389543Phase 1/2
- A Non-interventional,Observational Post Authorization Study of Patients With Multiple Myeloma Treated With Lenalidomide TRStatus unknownNCT02387879
- Filanesib (ARRY-520) in Combination With Pomalidomide and Dexamethasone for Relapsed/Refractory (R/R) Multiple Myeloma (MM) PatientsCompletedNCT02384083Phase 1/2
- A Study of VLX1570 and Dexamethasone in Myeloma PatientsTerminatedNCT02372240Phase 1/2
- Expanded Access Treatment Protocol CA204-143No longer availableNCT02368301
- CyBorD vs. PAD in the Treatment of Newly Diagnosed Multiple MyelomaStatus unknownNCT02362165Phase 3
- Kidney Therapy for Free Light Chain Removal in Patients With Multiple Myeloma & Cast NephropathyCompletedNCT02358980
- Open-label Extended Access Program on Lenalidomide Plus Dexamethasone in Chinese Subjects With Relapsed/Refractory Multiple Myeloma Who Participated in CC-5013-MM021 for at Least 1 YearCompletedNCT02348528Phase 2
- CDD Plus Bortezomib or CDDin Relapsed or Refractory Multiple Myeloma With Extramedullary PlasmacytomaStatus unknownNCT02336386Phase 3
- SVN53-67/M57-KLH Peptide Vaccine in Treating Patients With Newly Diagnosed Multiple Myeloma Receiving Lenalidomide Maintenance TherapyActive, not recruitingNCT02334865Phase 1
- Phase Ib Study of SAR650984 in Combination With Carfilzomib for Treatment of Relapsed or Refractory Multiple MyelomaCompletedNCT02332850Phase 1
- Carfilzomib/Cyclophosphamide/Dexamethasone with Maintenance Carfilzomib in Multiple MyelomaActive, not recruitingNCT02315716Phase 2
- Bendamustine Hydrochloride in Treating Patients With Previously Treated Multiple MyelomaWithdrawnNCT02315157Phase 1
- Nonmyeloablative Allogeneic Stem Cell Transplant Followed by Bortezomib in High-risk Multiple Myeloma PatientsCompletedNCT02308280Phase 2
- Study of Carfilzomib Weekly Plus Melphalan and Prednisone in Untreated Symptomatic Elderly Multiple MyelomaCompletedNCT02302495Phase 2
- B-Cell Hematologic Malignancy Vaccination RegistryWithdrawnNCT02298816
- Study of the Immune Response After Vaccination in Multiple Myeloma PatientsCompletedNCT02294487
- Weekly 70 mg/m2 Carfilzomib for Multiple Myeloma Patients Refractory to 27 mg/m2 CarfilzomibTerminatedNCT02294357Phase 2
- Blood Samples to Identify Biomarkers of BusulfanTerminatedNCT02291965
- Tumor-Associated Antigen-Specific Cytotoxic T-Lymphocytes for Multiple MyelomaActive, not recruitingNCT02291848Phase 1
- Tandem Melphalan and Autolog. SCT in MM Patients 60 to 70 Years of Age With and Without Induction ChemotherapyCompletedNCT02288741Phase 3
- Prolonged Protection From Bone Disease in Multiple MyelomaCompletedNCT02286830Phase 4
- SAR650984, Pomalidomide and Dexamethasone in Combination in RRMM PatientsCompletedNCT02283775Phase 1
- Dose Escalation Study of I-131-CLR1404 in Patients With Relapsed or Refractory Multiple MyelomaCompletedNCT02278315Phase 1
- Standard Care Alone or With Acupuncture for CIPN in Breast Cancer and Multiple MyelomaCompletedNCT02275403Phase 2
- Novel Support Options in Autologous Stem Cell Transplant for Multiple MyelomaCompletedNCT02274519Not applicable
- MSC and Cyclophosphamide for Acute Graft-Versus-Host Disease (aGVHD) ProphylaxisStatus unknownNCT02270307Phase 2/3
- A Pharmacokinetic Study of Bortezomib in Taiwanese Participants With Multiple MyelomaCompletedNCT02268890Phase 4
- Study Evaluating Venetoclax in Subjects With Hematological MalignanciesCompletedNCT02265731Phase 1/2
- Effects of Anticoagulant Preventive Injection in Patients With Blood CancerCompletedNCT02260414Phase 2
- A Phase I Open Label Study of the Safety and Tolerability of Elotuzumab (BMS-901608) Administered in Combination With Either Lirilumab (BMS-986015) or Urelumab (BMS-663513) in Subjects With Multiple MyelomaCompletedNCT02252263Phase 1
- Clarithromycin Plus CTd Regimen for Patients With Newly Diagnosed Multiple MyelomaStatus unknownNCT02248428Phase 3
- Autologous Dendritic Cell Therapy in Patients With Relapsed or Refractory Multiple MyelomaStatus unknownNCT02248402Phase 1/2
- A Multicenter Open Label Phase II Study of Pomalidomide and Cyclophosphamide and Dexamethasone in Relapse/Refractory Multiple Myeloma Patients Who Were First Treated Within the IFM/DFCI 2009 Trial (PCD)CompletedNCT02244125Phase 2
- Everolimus and Bendamustine Hydrochloride in Treating Patients With Relapsed or Refractory Hematologic CancerCompletedNCT02240719Phase 1
- Phase I Study of an Oncofetal Antigen Multi-Peptide Immunotherapy in Subjects With Hematologic CancerStatus unknownNCT02240537Phase 1
- Bendamustine, Prednisone and Velcade® for First-line Treatment of Patients With Symptomatic Multiple MyelomaCompletedNCT02237261Phase 2
- A Study Conducted in Subjects With Relapsed/Refractory Multiple Myeloma (MM); to Determine Dose of Afuresertib in Combination With Carfilzomib (Part 1) and to Investigate the Safety, Pharmacokinetic and Clinical Activity of the Combination Compared With Carfilzomib Alone (Part 2)TerminatedNCT02235740Phase 1
- A Phase IIa Study of Sotatercept on Bone Mass and Turnover in Patients With Multiple MyelomaWithdrawnNCT02230917Phase 2
- A Phase 1 Study Evaluating CB-5083 in Subjects With Lymphoid Hematological MalignanciesTerminatedNCT02223598Phase 1
- Bioequivalence & Food Effect Study in Patients With Solid Tumor or Hematologic MalignanciesCompletedNCT02223052Phase 1
- Plerixafor Plus Granulocyte Colony-stimulating Factor (G-CSF) For Mobilization And Collection Of Peripheral Hematopoietic Stem Cells In Japanese Participants With Multiple MyelomaCompletedNCT02221479Phase 2